Narendiran Rajasekaran
Overview
Explore the profile of Narendiran Rajasekaran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
272
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Magdaleno C, Tschumperlin D, Rajasekaran N, Varadaraj A
Sci Rep
. 2024 Dec;
14(1):31855.
PMID: 39738247
Idiopathic pulmonary fibrosis (IPF) is a fatal disease defined by a progressive decline in lung function due to scarring and accumulation of extracellular matrix (ECM) proteins. The SOCS (Suppressor Of...
2.
Magdaleno C, Tschumperlin D, Rajasekaran N, Varadaraj A
bioRxiv
. 2024 Mar;
PMID: 38469152
Idiopathic pulmonary fibrosis (IPF) is a fatal disease defined by a progressive decline in lung function due to scarring and accumulation of extracellular matrix (ECM) proteins. The SOCS (Suppressor Of...
3.
Rajasekaran N, Wang X, Ravindranathan S, Chin D, Tseng S, Klakamp S, et al.
Cancer Immunol Immunother
. 2024 Feb;
73(3):60.
PMID: 38400933
Over the past decade, US Food and Drug Administration (FDA)-approved immune checkpoint inhibitors that target programmed death-1 (PD-1) have demonstrated significant clinical benefit particularly in patients with PD-L1 expressing tumors....
4.
Cluff E, Magdaleno C, Fernandez E, House T, Swaminathan S, Varadaraj A, et al.
Cancer Immunol Immunother
. 2022 Jan;
71(8):1989-2005.
PMID: 34999917
Natural killer (NK) cells are cytotoxic innate lymphocytes that are specialized to kill tumor cells. NK cells are responsive to the primary cytokine IL-2 in the tumor microenvironment (TME), to...
5.
Vallania F, Zisman L, Macaubas C, Hung S, Rajasekaran N, Mason S, et al.
Front Immunol
. 2021 May;
12:659255.
PMID: 34054824
Monocytes are crucial regulators of inflammation, and are characterized by three distinct subsets in humans, of which classical and non-classical are the most abundant. Different subsets carry out different functions...
6.
Kofoed Andersen C, Khatri S, Hansen J, Slott S, Parvathaneni R, Mendes A, et al.
Pharmaceutics
. 2021 Apr;
13(4).
PMID: 33801590
Two types of single-walled carbon nanotubes (SWCNTs), HiPco- and carboxyl-SWCNT, are evaluated as drug carriers for the traditional anti-inflammatory drug methotrexate (MTX) and a small interfering RNA (siRNA) targeting NOTCH1...
7.
Magdaleno C, House T, Pawar J, Carvalho S, Rajasekaran N, Varadaraj A
J Cell Biochem
. 2021 Jan;
122(5):524-537.
PMID: 33438770
Fibronectin (FN) is an extracellular matrix (ECM) glycoprotein that self-assembles into FN fibrils, forming a FN matrix contributing to the stiffness of the ECM. Stromal FN stiffness in cancer has...
8.
Magdaleno C, Dixon L, Rajasekaran N, Varadaraj A
Sci Rep
. 2020 Oct;
10(1):18560.
PMID: 33122751
Fibronectin (FN) is a core matrix protein that assembles to form a dynamic cellular scaffold, frequently perturbed during oncogenic transformation. Tumor hypoxia, characterized by low oxygen concentrations in the microenvironment...
9.
Hebb J, Mosley A, Vences-Catalan F, Rajasekaran N, Rosen A, Ellmark P, et al.
Cancer Immunol Immunother
. 2017 Sep;
67(1):47-60.
PMID: 28905118
The delivery of immunomodulators directly into the tumor potentially harnesses the existing antigen, tumor-specific infiltrating lymphocytes, and antigen presenting cells. This can confer specificity and generate a potent systemic anti-tumor...
10.
Rajasekaran N, Chester C, Yonezawa A, Zhao X, Kohrt H
Immunotargets Ther
. 2016 Jul;
4:91-100.
PMID: 27471715
The therapeutic efficacy of some anti-tumor monoclonal antibodies (mAbs) depends on the capacity of the mAb to recognize the tumor-associated antigen and induce cytotoxicity via a network of immune effector...